HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. - Test2 - elhamkhani - TriplyDB

HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm.

HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm.

http://www.wikidata.org/entity/Q34621826

about

HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases Current clinical application of serum biomarkers to detect ovarian cancer The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomas Proteomics of ovarian cancer: functional insights and clinical applications Comprehensive serum profiling for the discovery of epithelial ovarian cancer biomarkers Key findings from the International Ovarian Tumor Analysis (IOTA) study: an approach to the optimal ultrasound based characterisation of adnexal pathology Towards an evidence-based approach for diagnosis and management of adnexal masses: findings of the International Ovarian Tumour Analysis (IOTA) studies Usefulness of diagnostic indices comprising clinical, sonographic, and biomarker data for discriminating benign from malignant ovarian masses.Comparison of serum human epididymis protein 4 and carbohydrate antigen 125 as markers in ovarian cancer: A meta-analysis.Preoperative evaluation of risk of ovarian malignancy algorithm index in prediction of malignancy of adnexal masses Threonyl-tRNA synthetase overexpression correlates with angiogenic markers and progression of human ovarian cancer Survival Advantage Associated with Decrease in Stage at Detection from Stage IIIC to Stage IIIA Epithelial Ovarian Cancer Improving strategies for diagnosing ovarian cancer: a summary of the International Ovarian Tumor Analysis (IOTA) studies.Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: a meta-analysis.Physiologic variations of serum tumor markers in gynecological malignancies during pregnancy: a systematic review.Presurgical diagnosis of adnexal tumours using mathematical models and scoring systems: a systematic review and meta-analysis.Comparison of HE4, CA125, and ROMA Diagnostic Accuracy: A Prospective and Multicenter Study for Chinese Women With Epithelial Ovarian Cancer.Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management Evaluation of ovarian cancer biomarkers HE4 and CA-125 in women presenting with a suspicious cystic ovarian mass.IGFBP-4 tumor and serum levels are increased across all stages of epithelial ovarian cancer.Major clinical research advances in gynecologic cancer in 2011.Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways.Multianalyte assay systems in the differential diagnosis of ovarian cancer.Preclinical evaluation of Mab CC188 for ovarian cancer imaging A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses.Differential diagnosis of a pelvic mass: improved algorithms and novel biomarkers Expression of HE4 in Endometrial Cancer and Its Clinical Significance Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study High preoperative blood levels of HE4 predicts poor prognosis in patients with ovarian cancer Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers Comparison of HE4, CA125, and Risk of Ovarian Malignancy Algorithm in the Prediction of Ovarian Cancer in Korean Women.Serial Patterns of Ovarian Cancer Biomarkers in a Prediagnosis Longitudinal Dataset Relative Quantification and Higher-Order Modeling of the Plasma Glycan Cancer Burden Ratio in Ovarian Cancer Case-Control Samples.Ovarian cancer: in search of better marker systems based on DNA repair defects Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response.Ovarian cancer: can proteomics give new insights for therapy and diagnosis?Biomarker testing for ovarian cancer: clinical utility of multiplex assays Clinical value of serum human epididymis protein 4 assay in the diagnosis of ovarian cancer: a meta-analysis.Preoperative HE4, CA125 and ROMA in the differential diagnosis of benign and malignant adnexal masses.Analysis of falsely elevated risk of ovarian malignancy algorithm in women with ovarian endometrioma.

P2860

Q24634978-1F9FC290-B8E8-49B4-9344-777B3BCC6056 Q26768709-E26F7E22-5BD2-4B0A-BE06-DB8293522CA2 Q26992102-63C1A06A-80D8-4705-8A85-522FF3BB610E Q28082632-D08BE914-1ECB-40CE-982B-9EC37FAAD735 Q28741004-273982EE-8E76-4800-B788-EC88A0BD3E9F Q30363494-3DCD8045-B66A-49B2-BBF4-2DA1E70B9E3C Q30414041-A1D0A79E-68E6-441A-B286-3F5EC233DC7B Q30885682-FBCDBF6B-8A3C-48D6-B8F2-E35065FE8C40 Q33733786-30997814-819C-4276-BC66-723F9FDC183F Q33918256-F440C2D8-8577-486C-826A-C0F4513CF3A0 Q34135915-E7F6451B-CF67-435F-B6BA-4B04FAC2B647 Q34196183-FE653CF8-EF87-497A-B7CA-496CCC61AAB4 Q34306120-E388A515-48EF-4668-8C09-62600B18958F Q34308808-1A8398DF-969B-47DC-B884-A19C1A65C408 Q34370883-BD80E3B5-5390-434E-8A50-B5809690D7FC Q34391119-4EDD1DFD-390B-4DFE-8326-F7D672981002 Q34675023-D5AD8560-B8DF-4CC5-A8B3-369A83DFBE52 Q35612779-23D014E2-7F1F-4772-9FD6-B3AFB3343303 Q35663640-287662B5-90A1-486B-8C96-E4380FD3DA10 Q35735751-AF5C48DB-9DCF-488D-B1F8-02BA2E6B5DB4 Q35758722-EB584B7A-FA5C-4AC8-9363-289C58E968C2 Q35837949-D054E5C4-C7A7-4F03-BFEF-2894FE5502FD Q35854476-1D00A1AB-165F-4DA4-B029-40F7E7E2BE10 Q35919110-03C134F5-4384-40E8-8F99-01018186F5F2 Q35956341-70971628-3EE8-4DBE-B2B5-8718A70BF1DB Q36076953-E61618EE-AE70-4193-A42D-8463958496D6 Q36204114-7D204274-B515-496D-8970-3E8F8D61C1B4 Q36229421-BB275C39-1670-4A4C-B514-DE31E8561F43 Q36346403-ECC4CC58-BEDF-404E-AF8A-76FB40F174BD Q36372283-B200314E-119B-4C65-A95B-F76D66AF77CB Q36400522-DDDC9898-0F79-40AD-83DA-51F771430323 Q36446886-89F299F2-DEF9-4CBC-A264-0F9297EAEAB0 Q36490028-AD97AD20-F59F-4D59-8E8C-200A20525E6C Q36589947-52940DC4-1707-4B0D-A29F-7B41574AAD16 Q36752512-920E6228-1D0D-4207-BFEE-BF7C918F9074 Q36820579-52E9687F-8D2F-43D4-BD2C-CEA619649422 Q36897149-7BBBD739-6A2A-4FFB-A0C6-A7F0635877A7 Q37053905-C9C460F5-8A6B-46E8-BB07-970C3BF914D2 Q37111350-0398A2FE-EFDA-4C48-9DCE-87BA7C1B9967 Q37121126-3EF5B8EA-5DEC-4362-9021-0B0AA43B7D9D

P2860

HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm.

http://www.wikidata.org/entity/Q34621826

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

HE4 and CA125 as a diagnostic ...... Ovarian Malignancy Algorithm.

@ast

HE4 and CA125 as a diagnostic ...... Ovarian Malignancy Algorithm.

@en

HE4 and CA125 as a diagnostic ...... Ovarian Malignancy Algorithm.

@nl

type

label

HE4 and CA125 as a diagnostic ...... Ovarian Malignancy Algorithm.

@ast

HE4 and CA125 as a diagnostic ...... Ovarian Malignancy Algorithm.

@en

HE4 and CA125 as a diagnostic ...... Ovarian Malignancy Algorithm.

@nl

prefLabel

HE4 and CA125 as a diagnostic ...... Ovarian Malignancy Algorithm.

@ast

HE4 and CA125 as a diagnostic ...... Ovarian Malignancy Algorithm.

@en

HE4 and CA125 as a diagnostic ...... Ovarian Malignancy Algorithm.

@nl

P1433

Q34621826-D1B9D67E-FF82-4FA8-BEE1-3B40DB62342B

P1476

Q34621826-3BB8B994-C85B-4C62-B7B5-6ACA52BE82F6

P2093

Q34621826-02C63623-D786-48C3-A390-0783A2782CAA

Q34621826-347C51A9-A872-4AC1-A717-D847D095E55A

Q34621826-3893FCB0-F303-4F08-8E25-AB21C2A60D37

Q34621826-6F4B7443-B1A7-4376-8F49-8163BF0A2FDB

Q34621826-724D1D7A-A97E-4579-9A5C-F084D42DCFB2

Q34621826-7FEA11E0-08BF-425B-98D2-ABE6CFEE16BA

Q34621826-AB79B476-7912-4FB0-9F91-2EA40EC8F05F

Q34621826-C5DB62F9-17B2-4ED5-B81D-2E48FC76A9DB

Q34621826-EC5F006E-4377-4CA9-80AB-EC086A6FC764

P2860

Q34621826-01C43D77-E060-446C-908D-3AAA193BC819

Q34621826-2383336B-42B5-4233-A183-54E73DD0DE84

Q34621826-2B24F203-2CFD-4881-B198-C8EF3CCCE06E

Q34621826-2F95BAE8-75C1-4757-8806-891837D4CEE1

Q34621826-3002F5B6-3B37-49F9-9E54-5B6B2613335C

Q34621826-34A5692F-AE82-46B2-9C79-7F35B277C453

Q34621826-4559DF03-5AE2-4EE5-BA8D-F3AA35DCC70F

Q34621826-631E454A-63B8-417B-A564-3B80C9ACE358

Q34621826-67BD28D1-5C14-4DFD-9B69-3D5CA0DCD15B

Q34621826-6FC314F1-5D7E-41F9-8A08-D3268460B68B

P2888

Q34621826-8454C8E6-441B-4813-B4FB-8BBF3BEA4238

P304

Q34621826-643EDDCF-2DBB-41BE-9757-DF3E71990FE6

P31

Q34621826-60F178A1-D5AB-4119-AF28-0702056CC380

P356

Q34621826-B5395DF1-7D36-4907-AA40-59E81F5101E1

P407

Q34621826-3B21FCE4-9381-4B14-9AB9-713152D9C299

P433

Q34621826-A04AA7EB-D668-4AFE-BD29-346B24A51738

P478

Q34621826-5F7E6739-66AF-48BC-9198-F838CD22491D

P577

Q34621826-5EC50D9A-7DB8-432E-ABBE-06366D7EA8B8

P5875

Q34621826-2C333320-2F0B-4459-BB59-1184768BE4F0

P6179

Q34621826-CA29ED91-6375-44EE-A883-D192224E9D7C

P698

Q34621826-AEB08523-8027-4ECB-9232-56906C9B7E69

P921

Q34621826-F2EAA169-4DF7-4672-9701-8A111C027690

Q34621826-e1b34a01-0524-4c4d-89bd-f984c65ace83

P932

Q34621826-7248F6AF-66DC-40F3-8367-B290B2BD5531

P356

P1433

British Journal of Cancer

P1476

HE4 and CA125 as a diagnostic ...... Ovarian Malignancy Algorithm.

@en

P2093

A Daemen

http://www.w3.org/2001/XMLSchema#string

B De Moor

http://www.w3.org/2001/XMLSchema#string

D Timmerman

http://www.w3.org/2001/XMLSchema#string

E Despierre

http://www.w3.org/2001/XMLSchema#string

F Amant

http://www.w3.org/2001/XMLSchema#string

I Cadron

http://www.w3.org/2001/XMLSchema#string

I Vergote

http://www.w3.org/2001/XMLSchema#string

K Leunen

http://www.w3.org/2001/XMLSchema#string

T Van Gorp

http://www.w3.org/2001/XMLSchema#string

P2860

Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts

Proteins with whey-acidic-protein motifs and cancer

Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach

Comprehensive analysis of HE4 expression in normal and malignant human tissues.

Systematic evaluation of candidate blood markers for detecting ovarian cancer.

Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer.

Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas.

The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms.

The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma.

A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.

P2888

P304

863-870

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6606092

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

104

http://www.w3.org/2001/XMLSchema#string

P577

2011-02-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49820581

http://www.w3.org/2001/XMLSchema#string

P6179

1020135853

http://www.w3.org/2001/XMLSchema#string

P698

21304524

http://www.w3.org/2001/XMLSchema#string

P921

P932

3048204

http://www.w3.org/2001/XMLSchema#string